“That's your take. Mine is that I think NASH will be so pronounced so quickly that is will be one one of the shortest clinical trials in the history of medicine.”

Again, the problem is enrollment. Leronlimab very well could show that type of efficacy but the trial needs to enroll all 90 patients before data can be released. If the trial can be fully enrolled by summer, we could get results by the end of next year. We’ll likely get an update on NASH trial enrollment during an upcoming CC and that’ll give us an idea on speed of enrollment.